Magnesium compositions and uses thereof for cognitive function
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-025/08
A01N-059/06
A61K-033/06
출원번호
US-0054367
(2008-03-24)
등록번호
US-8178118
(2012-05-15)
발명자
/ 주소
Liu, Guosong
Mao, Fei
출원인 / 주소
Magceutics, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
6인용 특허 :
11
초록▼
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of application
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
대표청구항▼
1. A method of enhancing cognitive function comprising administering to a subject a magnesium-containing compound (MCC) in an amount that is effective to enhance cognitive function, wherein the MCC comprises magnesium threonate. 2. The method of claim 1, further comprising measuring a body fluid con
1. A method of enhancing cognitive function comprising administering to a subject a magnesium-containing compound (MCC) in an amount that is effective to enhance cognitive function, wherein the MCC comprises magnesium threonate. 2. The method of claim 1, further comprising measuring a body fluid concentration of magnesium in the subject after fasting for at least about twelve hours, wherein said body fluid concentration is serum concentration, plasma concentration or cerebrospinal fluid concentration. 3. The method of claim 2, wherein said body fluid concentration is cerebrospinal fluid concentration. 4. The method of claim 1, wherein said magnesium-containing compound is a contained in magnesium-supplemented foodstuff. 5. The method of claim 1, wherein said cognitive function is short-term memory or long-term memory. 6. The method of claim 1, wherein said magnesium-containing compound is administered for a period of greater than 1 month. 7. A method of maintaining cognitive function comprising administering to a subject a magnesium-containing compound (MCC) in an amount that is effective to maintain cognitive function, wherein the MCC comprises magnesium threonate. 8. The method of claim 7, further comprising measuring a body fluid concentration of magnesium in the subject under a fasting condition, wherein said body fluid concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration. 9. The method of claim 8, wherein said body fluid concentration is cerebrospinal fluid concentration. 10. The method of claim 7, wherein said magnesium-containing compound is contained in a magnesium-supplemented foodstuff. 11. The method of claim 7, wherein said magnesium-containing compound is administered for a period of greater than 4 months. 12. The method of claim 7, further comprising the step of determining a starting body fluid concentration of magnesium of said subject under a fasting condition, wherein said starting body fluid concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration. 13. A method of therapeutic treatment of cognitive dysfunction or prophylactic treatment of magnesium deficiency-caused cognitive dysfunction, comprising administering to a subject in need of therapeutic or prophylactic treatment of cognitive dysfunction magnesium threonate in an amount that is effective for therapeutic or prophylactic treatment of said cognitive dysfunction. 14. The method of claim 13, wherein magnesium threonate is administered for at least about 1 month. 15. The method of claim 13, wherein magnesium threonate is administered for at least about 4 months. 16. The method of claim 13, further comprising measuring a body fluid concentration of magnesium after fasting for at least about 8 hours, wherein said body fluid concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration. 17. The method of claim 1, wherein the subject is an adult. 18. The method of claim 1, wherein the subject is a patient suffering from or diagnosed with dementia. 19. The method of claim 1, wherein the subject is a patient suffering from or diagnosed with Alzheimer's disease.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (11)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.